Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01406938 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 967
- Enrollment target
NCT01406938 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 967 participants.
The verdict
NCT01406938, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 967 participants
- Enrollment target
Study Summary
This study will assess the safety and efficacy of two different doses and two different dose regimens of subcutaneous secukinumab in patients that have moderate to severe, chronic, plaque-type psoriasis.
Interventions
- DRUG AIN457 150mg
- DRUG AIN457 300mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 967 participants |
| Start Date | 2011-08 |
| Est. Completion | 2013-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01406938
The ClinicalTrials.gov registry entry for NCT01406938 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 967 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AIN457 150mg is the first listed.
NCT01406938 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01406938 about?
NCT01406938 is a clinical study titled "Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens". This study will assess the safety and efficacy of two different doses and two different dose regimens of subcutaneous secukinumab in patients that have moderate to severe, chronic, plaque-type psoriasis.
What is the current status of trial NCT01406938?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 967 participants. The study started on 2011-08. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01406938?
The interventions under investigation include: AIN457 150mg (DRUG), AIN457 300mg (DRUG).
Who is sponsoring clinical trial NCT01406938?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.